Stoke Therapeutics (STOK) Share-based Compensation (2018 - 2026)

Stoke Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $8.8 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 29.62% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $34.2 million (up 18.57% YoY), while the FY2025 annual figure was $32.2 million, up 17.09% from the prior year.
• Share-based Compensation was $8.8 million for Q1 2026 at Stoke Therapeutics, down from $9.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.8 million in Q4 2025 to a low of $5.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $6.9 million across 5 years, with a median of $6.8 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation surged 6118.75% in 2022, then retreated 8.1% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $5.8 million in 2022, then rose by 4.63% to $6.1 million in 2023, then grew by 18.34% to $7.2 million in 2024, then surged by 36.84% to $9.8 million in 2025, then retreated by 10.77% to $8.8 million in 2026.
• The last three Share-based Compensation figures came in at $8.8 million (Q1 2026), $9.8 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.